01 — At a Glance
A Pharmaceutical Company That Quietly Prints Cash Since 1936
- 52-Week High / Low₹528 / ₹330
- Q3 FY26 Revenue₹465 Cr
- Q3 FY26 PAT₹43.7 Cr
- Full-Year FY25 EPS₹16.39
- Annualised EPS (Q3×4)₹6.96
- Book Value₹149
- Price to Book2.34x
- Dividend Yield1.44%
- Debt / Equity0.01x
- Recent 1-Yr Return-9.73%
The Plot Twist Nobody Expected: FDC is a 88-year-old pharmaceutical company that manufactures Electral (which corners 70.6% of India’s ORS market, no big deal), owns market-leading positions in Zifi, Enerzal, and a dozen other brands your doctor prescribes weekly — and yet trading at 24.2x P/E on ₹16.39 annualised FY25 EPS. ROE of 11.8%. Working capital days improved from 44 to 33 days. But the stock is down -9.73% over the past 12 months because the market apparently forgot that cash-generative, debt-free pharmaceutical companies exist. Welcome to small-cap India.
02 — Introduction
The Un-Sexy Pharmaceutical Company That Your Doctor Knows, But You Don’t.
FDC Limited. Founded 1936. Still headquartered in Mumbai. Not listed on your retail investor’s radar. You’ve never heard of them. Your parents have never heard of them. But your doctor? Your doctor prescribes their stuff every single day.
Here’s what you need to know: Electral is India’s dominant ORS (Oral Rehydration Salts) brand. It’s the thing you drink when you have gastro. Market share? 71%. Not 20%. Not 50%. Seventy-one percent. In a category where competitors include Walyte, Prolyte, and ORS that your neighbourhood chemist keeps in a dusty corner. Zifi (antibiotic) is a category leader in Cefixime. Enerzal (energy drink) dominates its segment. The company runs 7 manufacturing facilities, exports to 50+ countries, and has the cleanest balance sheet in pharma.
Q3 FY26 results arrived in Feb 2026 (because they report Jan-Dec financial year, which is weird for a publicly listed company, but we’ll talk about that later). Revenue of ₹465 crore. PAT of ₹43.7 crore. EPS of ₹1.74 (down from ₹2.38 in Q2 FY26 — but more on that). Working capital cycle improved from 53 days to 33 days. FDA approval for Fluconazole tablets. Another ANDA approval for Pilocarpine ophthalmic solution. A ₹140 crore capex approved for liquid oral facility expansion.
Translation: The machine keeps turning. The cash keeps flowing. The stock keeps flattering.
The Real Question: Is FDC underpriced because the market doesn’t understand pharmaceutical businesses? Or overpriced because everyone who DOES understand them is chasing hypergrowth stories in SaaS and AI instead? Your answer here determines whether this article is called “Hidden Gem” or “Value Trap.” Spoiler: we’ll do the math and you decide.
03 — Business Model: What Do They Even Make?
They Make The Stuff Your Stomach Needs. And Your Doctor Doesn’t Miss.
FDC is a vertically integrated pharmaceutical company split into three parts: Domestic Formulations (83% of revenue), International Formulations (13%), and APIs (4%).
Domestic Formulations (₹836 cr in H1 FY24): Anti-infective medicines (42% of domestic revenue) — your Zifi, Zathrin, Zifi-O. Gastro-intestinal (24%) — Electral, Enerzal, the stuff that stops your intestines from staging a rebellion. Vitamins/Minerals (7%), Ophthalmology (6%), Cardiac (7%), Dermatology (4%), and others (11%). FDC has 4,800 sales reps beating the pavement to convince doctors that their formulations are worth prescribing. 13 brands with ₹50+ crore annual sales. This is not basement operation. This is professional pharmacy.
International Formulations (₹144 cr in H1 FY24): 8 FDA ANDA approvals. 401 products registered across 51 countries. USA contributes 53% of export sales, followed by Ethiopia, Malaysia, UK, New Zealand, and others. The company has offices in London and South Africa. Manufacturing approvals from USFDA, UKMHRA, and other global regulators. This is World Pharma, not local-level distribution.
APIs (₹41 cr in H1 FY24): Active Pharmaceutical Ingredients. The raw material that other companies use to make formulations. FDC manufactures these at Roha (USFDA and WHO approved), Baddi (USFDA-compliant), and distributes globally. APIs grew 35% YoY in FY23. Backward integration done right.
Electral ORS71%Market Share
Zifi Cefixime25.4%Market Share
Enerzal Energy50%Market Share
Overall Dominance13 Brands₹50+ Cr Sales
R&D Spend Note: FDC spends 2-3% of turnover on R&D. Indian pharma industry average is 8-13%. This isn’t laziness. FDC is optimised for operational efficiency, not reinvention. The company has been making ORS since 1977. They know what they’re doing. Result: higher margins, lower capex intensity, better capital efficiency than R&D-heavy peers.
💬 Does a 71% market share in ORS feel comforting (dominant position) or scary (peak market, nowhere to grow)? What’s your take?
04 — Financials Overview
Q3 FY26: The Quarterly Deep Dive
